[Adenovirus-mediated interleukin-24 enhances the inhibitory effect of paclitaxel on the growth of lung cancer A549 cells].
OBJECTIVE
To investigate the effect of adenovirus-mediated interleukin-24 (Ad-IL-24) combined with paclitaxel on the growth of human lung cancer A549 cells in vitro.


METHODS
A549 cells were treated with Ad-IL-24 alone, paclitaxel alone and Ad-IL-24 combined with paclitaxel, respectively. Their proliferation was detected by CCK-8 assay, and the changes of apoptosis and cell cycle were tested by flow cytometry.


RESULTS
The treatment of Ad-IL-24 significantly inhibited the A549 cell growth and induced cell apoptosis. Compared with paclitaxel alone and Ad-IL-24 alone, the Ad-IL-24 plus paclitaxel treatment more evidently inhibited lung cancer cell growth and increased cell apoptosis rate, and induced G2/M phase arrest.


CONCLUSIONS
Ad-IL-24 infection can enhance the inhibitory effect of paclitaxel on lung cancer cell growth.
Zhuhai Campus, Zunyi Medical College, Innovation Base of Immunology for Graduate Education in Guizhou Province, Zhuhai 519041, China.
Mingju
M
Xu
Zhuhai Campus, Zunyi Medical College, Innovation Base of Immunology for Graduate Education in Guizhou Province, Zhuhai 519041, China.
Minmin
M
Li
Department of Cell and Molecular Biology, School of Biology and Basic Medical Sciences, Medical College, Soochow University, Suzhou 215123, China.
Jicheng
J
Yang
Zhuhai Campus, Zunyi Medical College, Innovation Base of Immunology for Graduate Education in Guizhou Province, Zhuhai 519041, China.
Jinjin
J
Guo
Zhuhai Campus, Zunyi Medical College, Innovation Base of Immunology for Graduate Education in Guizhou Province, Zhuhai 519041, China.
Wanbang
W
Sun
D000256:Adenoviridae / Q000235:genetics; D000972:Antineoplastic Agents, Phytogenic; D017209:Apoptosis; D059447:Cell Cycle Checkpoints / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D003131:Combined Modality Therapy; D015316:Genetic Therapy; D006801:Humans; D007378:Interleukins / Q000235:genetics*; D008175:Lung Neoplasms / Q000473:pathology / Q000628:therapy*; D017239:Paclitaxel / Q000494:pharmacology*; D000099180:Interleukin-24
D000972:Antineoplastic Agents, Phytogenic; D007378:Interleukins; D017239:Paclitaxel; D000099180:Interleukin-24